Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
170.8 USD | -1.15% |
|
-0.36% | +10.18% |
25/06 | FDA Again Rejects AbbVie Parkinson's Drug/Pump Combo -- Update | DJ |
25/06 | AbbVie Issues Regulatory Update on New Drug Application for ABBV-951 to Treat Parkinson's Disease | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.18% | 31TCr | |
+55.19% | 80TCr | |
+47.26% | 63TCr | |
-6.09% | 36TCr | |
+21.92% | 34TCr | |
+18.40% | 25TCr | |
+3.64% | 23TCr | |
+12.98% | 22TCr | |
+10.86% | 17TCr | |
-2.78% | 16TCr |
- Stock Market
- Equities
- ABBV Stock
- News AbbVie Inc.
- AbbVie Says First Patient Treated in Phase 3 Trial Assessing Potential Blood Cancer Treatment